Business Standard
Home / India News / Ranbaxy to manufacture and market Fenofibrate Capsules USP 43 mg and 130 mg

Ranbaxy to manufacture and market Fenofibrate Capsules USP 43 mg and 130 mg

Image

Capital Market
Last Updated : Nov 05 2014 | 9:38 PM IST

After USFDA approval

Ranbaxy Laboratories announced that the Company has received approval from the USFDA to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg.

Powered by Capital Market - Live News

Also Read

Ranbaxy posts Q2 profit

Ranbaxy posts Q2 profit

Ranbaxy posts loss on provision for U.S. settlement

Ranbaxy posts loss on provision for U.S. settlement

Ranbaxy Laboratories posts loss in June quarter

Ranbaxy Laboratories posts loss in June quarter

Ranbaxy posts March-quarter loss on write-offs

Ranbaxy posts March-quarter loss on write-offs

Ranbaxy posts loss after write-offs on US import bans

Ranbaxy posts loss after write-offs on US import bans

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 05 2014 | 4:05 PM IST

Explore News

Market LIVEMarket TodayIndia vs Pakistan LIVEParliament Winter Session 2024 LIVELatest News LIVEStocks To Watch TodayProcess to withdraw PF by ATMGold-Silver Price TodayIPO NewsBusiness Standard at 50
HOT STOCKS
TOP SECTIONS
KEY EVENTS
Copyrights © 2024 Business Standard Private Ltd. All rights reserved
LinkedIN Icon